Pasithea Therapeutics Corp's KTTA wholly-owned subsidiary, Pasithea Clinics, has administered intravenous (IV) ketamine therapy to its first patients with treatment-resistant depression.
Pasithea Clinics commenced IV ketamine infusion therapy in Knightsbridge, London.
In sub-anesthetic doses, ketamine has shown efficacy and a rapid and sustained effect in some psychiatric disorders, such as treatment-resistant depression and post-traumatic stress disorder.
Ketamine is an FDA-approved anesthetic and was introduced over 50 years ago. It has recently been repurposed in significantly lower doses to treat psychiatric disorders.
Pasithea has clinical partnerships to administer its IV ketamine treatment. In the U.K., Pasithea has partnered with ZEN Healthcare – a network of health clinics in London.
In the U.S., it has partnered with The IV Doc Inc to provide in-home IV ketamine infusions.
Related: EXCLUSIVE: Pasithea Therapeutics Launches First Ketamine Clinic In The UK.
Price Action: KTTA shares closed 1.50% higher at $2.71 on Tuesday.
Photo: Michaelberry via Wikimedia
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry? Hear directly for top executives, investors and policymakers at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.